Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Short term Debt (2016 - 2026)

Cytosorbents filings provide 7 years of Short term Debt readings, the most recent being $2.5 million for Q1 2024.

  • On a quarterly basis, Short term Debt changed N/A to $2.5 million in Q1 2024 year-over-year; TTM through Mar 2024 was $2.5 million, a N/A change, with the full-year FY2023 number at $2.5 million, changed N/A from a year prior.
  • Short term Debt hit $2.5 million in Q1 2024 for Cytosorbents, roughly flat from $2.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.2 million in Q3 2020 to a low of $833333.0 in Q3 2023.
  • Median Short term Debt over the past 3 years was $3.3 million (2020), compared with a mean of $4.3 million.
  • The widest YoY moves for Short term Debt: up 700.0% in 2020, down 150.0% in 2020.
  • Cytosorbents' Short term Debt stood at $9.2 million in 2020, then crashed by 72.73% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024.
  • The last three reported values for Short term Debt were $2.5 million (Q1 2024), $2.5 million (Q4 2023), and $833333.0 (Q3 2023) per Business Quant data.